[Federal Register Volume 67, Number 14 (Tuesday, January 22, 2002)]
[Notices]
[Pages 2891-2892]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-1409]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Peripheral and Central Nervous System Drugs Advisory Committee; 
Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Peripheral and Central Nervous System Drugs 
Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on February 15, 2002, from 
8 a.m. to 5 p.m.
    Location: Holiday Inn, The Ballroom, Two Montgomery Village Ave., 
Gaithersburg, MD.
    Contact: Sandra Titus, Center for Drug Evaluation and Research 
(HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express 
delivery, 5630 Fishers Lane, rm. 1093) Rockville, MD 20857, 301-827-
7001, or e-mail [email protected], or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area) code 12543. Please call the Information Line for up-to-date 
information on this meeting.
    Agenda: The committee will consider the safety and efficacy of 
biologics license application (BLA) 103780/0 REBIF (Interferon beta-1A, 
Serono), proposed for the treatment of relapsing-remitting multiple 
sclerosis. The background material will become available the day before 
the meeting and it will be posted under the Peripheral and Central 
Nervous System Drugs Advisory Committee Docket site at: http://www.fda.gov/ohrms/dockets/ac/acmenu.htm. (Click on the year 2002 and 
scroll down to the Peripheral and Central Nervous System Drugs 
meetings.)
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by February 1, 
2002. Oral presentations from the public will be scheduled from 
approximately 11 a.m. to 12 noon. Time allotted for each presentation 
may be limited. Those

[[Page 2892]]

desiring to make formal oral presentations should notify the contact 
person before February 1, 2002, and submit a brief statement of the 
general nature of the evidence or arguments they wish to present, the 
names and addresses of proposed participants, and an indication of the 
approximate time requested to make their presentation.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: January 10, 2002.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 02-1409 Filed 1-18-02; 8:45 am]
BILLING CODE 4160-01-S